Form 4 for IDXX Idexx Laboratories
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000874716-26-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-19 | 2026-02-17+ | IDXX | Erickson Michael G | EVP | M - OptEx | $187.94 | +7,770 | 14.7K | +112% | +$1.46M |
| DM | 2026-02-19 | 2026-02-17 | IDXX | Erickson Michael G | EVP | S - Sale+OE | $627.38 | -5,371 | 12.7K | -30% | -$3.37M |
| DM | 2026-02-19 | 2026-02-17+ | IDXX | Erickson Michael G | EVP | M - OptEx | $0.00 | -7,770 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | M | A | 1,191 | $141.60 | 13,884.35 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | M | A | 4,180 | $178.26 | 18,064.35 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-19 | M | A | 197 | $505.53 | 15,092.35 | D | — | — | (F6) Includes 184 vested but deferred restricted stock units. |
| 4 | Common | Common Stock | 2026-02-19 | M | A | 183 | $544.08 | 14,895.35 | D | — | — | |
| 5 | Common | Common Stock | 2026-02-17 | S | D | 456 | $623.76 | 17,608.35 | D | — | — | (F1) Represents the weighted average price of the shares sold ranging from a low of $623.28 to a high of $624.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 6 | Common | Common Stock | 2026-02-17 | S | D | 204 | $625.24 | 17,404.35 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $624.89 to a high of $625.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 7 | Common | Common Stock | 2026-02-17 | S | D | 1,288 | $626.26 | 16,116.35 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $626.045 to a high of $628.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 8 | Common | Common Stock | 2026-02-17 | S | D | 2,694 | $628.22 | 13,422.35 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $627.74 to a high of $628.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 9 | Common | Common Stock | 2026-02-17 | S | D | 689 | $629.09 | 12,733.35 | D | — | — | (F5) Represents the weighted average price of the shares sold ranging from a low of $628.755 to a high of $629.615 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 10 | Common | Common Stock | 2026-02-17 | S | D | 40 | $629.86 | 12,693.35 | D | — | — | |
| 11 | Common | Common Stock | 2026-02-19 | M | A | 719 | $141.60 | 13,412.35 | D | — | — | |
| 12 | Common | Common Stock | 2026-02-19 | M | A | 817 | $178.26 | 14,229.35 | D | — | — | |
| 13 | Common | Common Stock | 2026-02-19 | M | A | 483 | $206.94 | 14,712.35 | D | — | — | |
| 14 | Derivative | Incentive Stock Option (right-to-buy) | 2026-02-19 | M | D | 483 | $0.00 | 0 | D | $206.94 · — to 2029-02-13 | 483 Common Stock | (F11) Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. |
| 15 | Derivative | Incentive Stock Option (right-to-buy) | 2026-02-19 | M | D | 183 | $0.00 | 0 | D | $544.08 · — to 2031-02-13 | 183 Common Stock | (F12) Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2025. |
| 16 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2026-02-17 | M | D | 4,180 | $0.00 | 0 | D | $178.26 · — to 2028-02-13 | 4,180 Common Stock | (F8) Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2019. |
| 17 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2026-02-17 | M | D | 1,191 | $0.00 | 0 | D | $141.60 · — to 2027-02-13 | 1,191 Common Stock | (F7) Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018. |
| 18 | Derivative | Incentive Stock Option (right-to-buy) | 2026-02-19 | M | D | 817 | $0.00 | 0 | D | $178.26 · — to 2028-02-13 | 817 Common Stock | (F10) Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2023. |
| 19 | Derivative | Incentive Stock Option (right-to-buy) | 2026-02-19 | M | D | 719 | $0.00 | 0 | D | $141.60 · — to 2027-02-13 | 719 Common Stock | (F9) Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2022. |
| 20 | Derivative | Incentive Stock Option (right-to-buy) | 2026-02-19 | M | D | 197 | $0.00 | 0 | D | $505.53 · — to 2032-02-13 | 197 Common Stock | (F13) Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2026. |